Holen Sie sich die Stockscreener-App
0.4612
7.13%
-0.0354
Handel nachbörslich:
.47
0.0088
+1.91%
Scinai Immunotherapeutics Ltd Adr Aktie (SCNI) Neueste Nachrichten
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Sahm
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Benzinga
Scinai Immunotherapeutics schedules annual shareholder meeting for June 16 - Investing.com
NASDAQ gains over 100 points; Intel shares jump after strong Q1 results - MSN
Tangible book value per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today - Sahm
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Finviz
Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results - Benzinga
Scinai raises $2.61M in private placement to expand CDMO unit - Investing.com
Scinai raises $2.61M in private placement to expand CDMO unit By Investing.com - Investing.com South Africa
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Sahm
Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations - Contract Pharma
Scinai completes corporate reorganization, separates CDMO unit By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Total debt per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Scinai completes corporate reorganization, separates CDMO unit - Investing.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Barchart.com
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Sahm
Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 - Finviz
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Barchart.com
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Barchart.com
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Enerflex (NYSE:EFXT) Shares Gap Up Following Dividend Announcement - Defense World
Scinai receives expanded grant for robotic manufacturing system - Investing.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Finviz
Scinai Immunotherapeutics Buys Recipharm Israel - Contract Pharma
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Finviz
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Finviz
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Finviz
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Scinai Announces Annual Financial Results for 2024 - Finviz
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):